The recommendation of Adcetris (brentuximab vedotin) represents the first new frontline therapy for systemic anaplastic large cell lymphoma (sALCL) in several decades.
List view / Grid view
Adcetris (brentuximab vedotin)
Filter the results
A report states that three quarters of the roughly 230 nanopharmaceuticals in clinical development are for use as targeted cancer therapeutics.
The US Food and Drug Administration has approved first-line treatment for newly diagnosed peripheral T-cell lymphoma using a new review program...